Inhibrx

INBX

시가총액 US$13.2억

SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 2026 European Society for Medical Oncology (ESMO) Congress October 25 th , 2026 – Madrid, Spain Title: HexAgon-HN: a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1–high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)—phase 2 primary analysis Format: Oral Presentation Lead Author: Jong Chul Park Date and Time: Sunday, October 25th, 2026; 8:30-10:00 AM CET 2026 Musculoskeletal Tumor Society (MSTS) Annual Meeting October 29 th , 2026 – Miami, Florida Title: The Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Secondary Efficacy Endpoints from the Randomized, Registrational, Phase 2 ChonDRAgon study Format: Oral Presentation Lead Author: Robin Jones Date and Time: Thursday, October 29th, 2026; 2:50-3:40 PM EST 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting November 19 th – 20 th , 2026 – Seoul, South Korea Title: Tetravalent Death Receptor 5 Agonist Ozekibart (INBRX-109) in Conventional Chondrosarcoma: Subgroup Analysis and Updated Progression-Free Survival (PFS) from the Randomized, Phase 2 ChonDRAgon Study Lead Author: Sant Chawla Format: Oral Presentation Date and Time: Friday, November 20th, 2026; 11:00 AM-12:30 PM KST Title: Phase 1/2 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined with Irinotecan (I) and Temozolomide (T) in Adolescents and Adults with Ewing Sarcoma (EWS) Lead Author: Varun Monga Format: Poster Presentation Date and Time: Thursday, November 19th, 2026; 5:30-6:30 PM KST The presentations and poster will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrxbiosciences.investorroom.com/events-and-presentations, upon commencement of each event. About Inhibrx Biosciences, Inc. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates.

Inhibrx Biosciences TodayINBXInhibrx Biosciences$97.93 -2.15 (-2.15%) As of 10/1/2026 04:00 PM Eastern52-Week Range$28.16▼$155.29Price Target$197.50Add to WatchlistAfter a decisive clinical outperformance that the broader market inexplicably sold off, Inhibrx Biosciences NASDAQ: INBX CEO deployed more than $3.6 million of personal capital to buy shares. With about 28% of the public float sold short and a major FDA approval date looming, this concentrated insider buying signals a high-probability valuation reset and sets the stage for a potential short squeeze.

The purchase of 25,000 shares for ~$2.6 million was executed at a weighted average price of $105.82 per share on September 8, 2026. The transaction size was equal to 3% of the total equity stake held before the filing.

Inhibrx Biosciences (INBX) maintains a "Strong Buy" rating, driven by major clinical and regulatory milestones for ozekibart and INBRX-106. Ozekibart's BLA for unresectable/metastatic chondrosarcoma was accepted by the FDA, with a PDUFA target action date of April 14, 2027. Company reported positive interim data for ozekibart in 3rd/4th-line CRC and strong phase 2 results for INBRX-106 plus KEYTRUDA in HNSCC.

Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk reduction in chondrosarcoma progression and strong response rates in colorectal and Ewing sarcoma cohorts, fueling prior share price surges. INBRX-106, combined with Keytruda, showed a 48.3% cORR in head and neck cancer in data shared yesterday, with pronounced efficacy in HPV+ patients, but market response remains muted.

Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study.

Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a ​mid-stage study in patients with a type of ‌head and neck cancer.

First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and   72.4% of patients remain progression free at 6 months, compared with 26.5% and   42.8%   for pembrolizumab alone Results are most pronounced in HPV+ patients, with   cORR (80.0% vs 33.3%), CR rate (30.0% vs 0%), and PFS6 improvement (90.0% vs 33.0%) vs pembrolizumab alone Inhibrx will expand the Phase 2 study by approximately 50 HPV+ patients   and may serve as   a potential pathway to accelerated   approval Positive results support large expansion opportunities   into highly immunogenic tumors and combination with cancer vaccines SAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).

– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.